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Cerebrospinal fluid (CSF) assessment is often part of 
the diagnostic workup for multiple sclerosis (MS), 
and its value is supported by the latest 2017 revisions 
of the McDonalds criteria.1 CSF examination is fre-
quently performed in diagnosing MS for excluding 
alternative diagnoses, although, in the current MS cri-
teria,2 the assessment of oligoclonal IgG bands (OCB) 
plays a limited role. However a recent study showed 
the added value of OCB in the MS diagnostic crite-
ria.3 In the 2017 revisions, the OCB have a prominent 
role in patients with a clinically isolated syndrome 
(CIS). The presence of both magnetic resonance 
imaging (MRI) criteria for dissemination in space 
(DIS) and CSF-specific OCB will enable to establish 
the MS diagnosis in patients with a single clinical epi-
sode suggestive of central nervous system (CNS) 
inflammatory demyelinating disease. The OCB 
assessment also has important prognostic value in 
CIS and MS.4,5 However, the assessment of OCB is 
labor-intensive, requires trained personnel, and is in 
some cases examiner- and method-dependent, which 
may affect its reliability.
Alongside intact immunoglobulins, which are com-
posed of two heavy and two light chains, plasma cells 
produce and secrete immunoglobulin free light 
chains (FLC) of either kappa (KFLC) or lambda 
(LFLC) chains. KFLC and LFLC can be detected in 
both CSF and serum.6–10 Since the late 1970s, 
Kappa free light chains is a valid tool in the 
diagnostics of MS: A large multicenter study
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Abstract
Objective: To validate kappa free light chain (KFLC) and lambda free light chain (LFLC) indices as a 
diagnostic biomarker in multiple sclerosis (MS).
Methods: We performed a multicenter study including 745 patients from 18 centers (219 controls and 
526 clinically isolated syndrome (CIS)/MS patients) with a known oligoclonal IgG band (OCB) status. 
KFLC and LFLC were measured in paired cerebrospinal fluid (CSF) and serum samples. Gaussian mix-
ture modeling was used to define a cut-off for KFLC and LFLC indexes.
Results: The cut-off for the KFLC index was 6.6 (95% confidence interval (CI) = 5.2–138.1). The cut-off 
for the LFLC index was 6.9 (95% CI = 4.5–22.2). For CIS/MS patients, sensitivity of the KFLC index 
(0.88; 95% CI = 0.85–0.90) was higher than OCB (0.82; 95%CI = 0.79–0.85; p < 0.001), but specificity 
(0.83; 95% CI = 0.78–0.88) was lower (OCB = 0.92; 95% CI = 0.89–0.96; p < 0.001). Both sensitivity and 
specificity for the LFLC index were lower than OCB.
Conclusion: Compared with OCB, the KFLC index is more sensitive but less specific for diagnosing 
CIS/MS. Lacking an elevated KFLC index is more powerful for excluding MS compared with OCB but 
the latter is more important for ruling in a diagnosis of CIS/MS.
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multiple studies have reported increased CSF levels 
of KFLC in MS.6–14 The analytical specificity of the 
earlier methods (e.g. radioimmunoassay,15,16 quanti-
tative enzyme-linked immunosorbent assay)8,17 was 
insufficient, but with the recent emergence of the 
more sensitive nephelometric and turbidimetric FLC 
assays, research in this field has been revived. 
Nephelometric (and turbidimetric) FLC level deter-
mination has the additional advantage compared to 
OCB of being assessed by an automated procedure 
and being quantifiable.18
Using the FLC assay,19 recent studies showed that 
both CSF KFLC levels and the KFLC index are 
increased in patients with CIS or relapsing-remitting 
MS (RRMS) compared with controls.8,14,18,20–22 The 
use of an index measure is necessary, for example 
[CSF KFLC/serum KFLC]/[CSF albumin/serum 
albumin], to include blood-CSF barrier permeabil-
ity.10,14 The KFLC index has comparable sensitivity 
and specificity to OCB for diagnosis of MS and 
CIS.14,21,23 However, large-scale studies comparing 
diagnostic performance of the two methods and to 
define the cut-off of FLC are lacking. The main aim 
of this study was to validate KFLC and LFLC indices 
as a diagnostic biomarker in MS compared with OCB 
in a large multicenter study including samples from 
18 MS centers across Europe.
Methods
Patients and controls
Eighteen MS centers participated, located in the 
Netherlands, Spain, France, Belgium, Hungary, Italy, 
Poland, Turkey, Denmark, Serbia, Austria, and 
Switzerland. We selected 745 paired CSF/serum sam-
ples from patients with known OCB status, diagnosed 
as CIS (n = 242), RRMS (n = 235), primary-progres-
sive MS (PPMS) (n = 41), and secondary-progressive 
MS (SPMS) (n = 8). We also included inflammatory 
neurological disease controls (INDC) (n = 67), non-
inflammatory neurological disease controls (NINDC) 
(n = 76), symptomatic controls (SC) (n = 49), and 
healthy controls (HC) (n = 27) as defined previously.24 
The different control groups were pooled into one 
control group (n = 219). The CIS and MS patients 
were also pooled (CIS/MS) (n = 526).
The large majority (84%) of the CIS/MS patients 
fulfilled the 2010 McDonald criteria2 but, in some 
cases, the patients were diagnosed according to the 
2005 McDonald criteria25 (16%). Table 1 presents 
the demographic and clinical characteristics of the 
patients and controls.
CSF and serum samples
Only CSF samples that were immediately centrifuged 
and stored in polypropylene tubes within 2 hours at 
−80°C, at the local center, were included. The assess-
ment of OCB had been performed by isoelectric 
focusing (on agarose or polyacrylamide gel), fol-
lowed by immunofixation by the centers as part of the 
diagnostic workup.
Samples were taken between 2005 and 2016, with a 
median age of 2.9 years (IQR = 1.7–5.7).
We used fresh aliquots, and in our lab, we did not 
freeze and thaw the samples during the analyses. As 
far as we know, no effects of freezing and thawing 
have been reported.
KFLC, LFLC, and albumin analysis
KFLC, LFLC, and albumin concentrations in CSF and 
serum samples were analyzed using the turbidimetric 
analyzer SPAplus® (The Binding Site, Birmingham, 
UK) with the serum free light chain immunoassay 
(Freelite®, The Binding Site, Birmingham, UK) 
according to the manufacturer’s instructions. All sam-
ples were measured centrally in the Neurochemistry 
Laboratory of the Department of Clinical Chemistry 
of the VU University Medical Center (VUmc), 
Amsterdam, the Netherlands. All samples were run 
blinded for the clinical data.
To verify the QC data supplied by the manufacturer, 
we calculated intra-assay coefficient of variation 
(CV) by taking the mean CVs of four replicates of 
five samples (CSF/serum) within one run. We calcu-
lated inter-assay CV based on n = 5 samples (CSF/
serum) measured in 5 different days. CV values for 
KFLC and LFLC were all found to be lower than 
those supplied by the manufacturer (Supplemental 
Table 1). CV values for albumin were comparable to 
those supplied by the manufacturer. Assay linearity 
was experimentally confirmed for albumin (serum 
and CSF) and the FLC assays in serum and showed 
that recalculated values varied by 25.7% (KFLC) and 
14.2% (LFLC) from the original value.
For 29 samples, CSF albumin results were below 
detection. Here, we assigned a random uniform value 
between 35 mg/mL (lowest detected value in undi-
luted rerun) and 175 mg/mL (formal detection limit).
FLC indices
We determined the CSF/serum quotients (Q FLC) of 
KFLC and LFLC and calculated indices in order to 
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take possible blood-CSF diffusion into account. The 
FLC indices were defined as [Q FLC] × [serum albu-
min/CSF albumin].
Statistics
Differences in demographics, clinical characteristics, 
FLC concentrations, and FLC indices were tested via 
the Mann–Whitney U test for comparison of two 
groups of non-normally distributed data. For compar-
ison of more than two groups, Kruskal–Wallis test 
with post hoc Dunn’s multiple comparison test was 
applied. For normally distributed continuous varia-
bles, an independent-samples t test or one-way analy-
sis of variance (ANOVA) with post hoc Bonferroni 
correction was applied. For binary variables, a chi-
square test was performed. These statistical analyzes 
were performed in SPSS 22.0 (IBM Crop., Armonk, 
NY, USA).
Gaussian mixture modeling was used to define cut-
offs for abnormal FLC indices using the R statistical 
software program version 3.2.1 mixtools package. 
First, the number of distributions that best described 
the data was determined with the R boot.comp func-
tion. Next, we defined a data-driven cut-off as the 
point where the lines of two fitted normal distribu-
tions crossed each other. The main analyses included 
all subjects. Data were log-transformed because FLC 
indices were not normally distributed. Based on the 
defined cut-off, subjects were classified as positive or 
negative for kappa or lambda FLC as binary result, 
similar as the available results for OCB status. As 
extra comparisons, we combined the different tools to 
compare with the single measurement OCB. The 
three combinations were as follows: KFLC with 
OCB, LFLC with OCB, and KFLC with LFLC. We 
defined the outcome of the combination as followed: 
when one of the measurements is positive, the combi-
nation is positive, when both are negative, the combi-
nation is negative.
To compare the sensitivity, specificity, and accuracy 
between the two different diagnostic tools (OCB and 
FLC), the McNemar test was used (SPSS 22.0 (IBM 
Crop., Armonk, NY, USA)). The positive and negative 
predictive values (PPVs and NPVs) were compared 
using the R package DTcompair. The p values < 0.05 
were considered statistically significant.
Results
Paired CSF and serum samples from a total of 745 
patients were included in this multicenter study (see 
Supplemental Figure 1 for the flowchart of patient 
selection). The patient groups (n = 526) consisted of 
242 CIS and 284 MS patients. The control group 
(n = 219) consisted of 76 NINDC, 67 INDC, 49 SC, 
and 27 HC. The control group was older 
(mean = 42 ± 12 years) than the CIS/MS patient group 
(mean = 35 ± 10 years, p < 0.001). There was no sig-
nificant difference in sex distribution between the two 
groups (p = 0.20). Only 7.7% of the control group had a 
positive OCB status. The diagnoses of these patients 
are as follows: Tolosa hunt (n = 2), meningitis (n = 1), 
neurosarcoidosis (n = 2), lupus (n = 1), transient global 
amnesia (n = 1), stroke (n = 1), post-infectious myelitis 
(n = 1), myelitis (n = 1), encephalitis (n = 1), epilepsy 
(n = 1), ADEM (n = 1), neurodegeneration (n = 1), 
INDC, exact diagnosis unknown (n = 2), and neuritis 
optica (n = 1).
Table 2. FLC in CIS/MS and controls.
A CIS/MS (n = 526) Controls (n = 219) p-value
CSF KFLC (mg/L) 3.7 (1.0–10.1) 0.2 (0.1–0.4) <0.001
Serum KFLC (mg/L) 12.4 (9.8–15.7) 13.7 (10.6–16.9) 0.001
KFLC index 75.6 (21.8–197.0) 2.8 (2.2–4.9) <0.001
KFLC index ⩾ 6.6 460 (87.5) 38 (17.4) –
B CIS/MS (n = 543) Controls (n = 202) p-value
CSF LFLC (mg/L) 0.5 (0.2–1.3) 0.2 (0.2–0.3) < 0.001
Serum LFLC (mg/L) 11.3 (9.2–13.7) 12.1 (9.8–15.4) 0.001
LFLC index 11.6 (5.3–33.3) 3.3 (2.5–4.7) < 0.001
LFLC index ⩾ 6.9 359 (68.3) 30 (13.7) –
FLC: free light chains; CIS: clinically isolated syndrome; MS: multiple sclerosis; A: KFLC in CIS/MS and controls; CSF: cerebrospi-
nal fluid; KFLC: kappa free light chain; index: FLC quotient/albumin quotient; B: LFLC in CIS/MS and controls; LFLC: lambda free 
light chains; IQR: interquartile range.
Values are given as n (%) or as median (IQR).
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For a detailed list including the diagnoses of non-
inflammatory neurological diseases and inflamma-
tory neurological diseases included in the groups, see 
Supplemental Tables 2A and 2B.
FLC concentrations and FLC indices
Table 2 shows the levels and indices of the KFLC and 
LFLC in CIS/MS patients and controls. CSF KFLC 
and CSF LFLC concentrations were significantly 
increased in CSF of CIS/MS patients compared to 
controls (both p < 0.001). In addition, KFLC and 
LFLC concentrations in CSF were higher in MS 
patients than CIS patients (both p < 0.001).
KFLC and LFLC serum concentrations were signifi-
cantly higher in the control group than CIS/MS (both, 
p = 0.001) but did not differ significantly between CIS 
and MS (KFLC p = 0.33, LFLC p = 1.00).
See Figure 1(a) for the KFLC indices per subgroup 
and Figure 1(b) for the LFLC indices per subgroup. 
KFLC and LFLC indices were significantly increased 
in CIS/MS compared to controls (both p < 0.001). In 
addition, FLC indices were higher in MS than in CIS 
(KFLC p = 0.07, LFLC p < 0.001).
FLC index cut-off
In the total cohort (n = 745) (all diagnostic subgroups), 
a bimodal distribution of the log-transformed KFLC 
index values fitted the data best. This yielded a cut-off 
for the log-KFLC index of 1.89 (95% confidence 
interval (CI) = 1.65–4.92) (Figure 2(a)), which corre-
sponds to an KFLC index of 6.6 (95% CI = 5.2–138.1) 
on the original scale.
For the LFLC index, a bimodal distribution yielded an 
optimal cut-off for the log-LFLC index of 1.9 (95% 
Figure 1. CSF KFLC and LFLC indices of CIS, MS, CIS/MS and controls. (a) Levels of KFLC indices, (b) levels of 
LFLC indices. Horizontal bars in the scatter dot plot represent the median.
CSF: cerebrospinal fluid; KFLC: kappa free light chains; LFLC: lambda free light chains; CIS: clinically isolated syndrome; MS: 
multiple sclerosis.
*p ⩽ 0.001.
Figure 2. Cerebrospinal fluid (a) KFLC and (b) LFLC cut-off values based on mixture modeling. The red (low values) 
and green (high values) lines are the individual components of the estimated mixture distributions, the dotted line is the 
combined estimated mixture distribution. The cut-off is defined as the point where the red and green lines cross.
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CI = 1.5–3.1) (Figure 2(b)), which corresponds to an 
LFLC index of 6.9 (95% CI = 4.5–22.2) on the origi-
nal scale.
Diagnostic sensitivity and specificity of the 
indices compared to OCB
KFLC index. When pooling CIS and MS as one 
group (CIS/MS), the sensitivity to identify CIS/
MS from controls of the KFLC index (0.88) was 
significantly higher than of OCB (0.82; p < 0.001) 
at the cost of a significantly lower specificity 
(KFLC index = 0.83, OCB = 0.92; p < 0.001) (see 
Table 3).
When identifying CIS patients from controls, the 
sensitivities did not differ significantly between 
KFLC and OCB (KFLC index = 0.81, OCB = 0.77; 
p = 0.15), but the specificity of OCB was significantly 
higher (KFLC index = 0.83, OCB = 0.92, p < 0.001). 
Identifying MS patients from controls, the sensitivity 
of the KFLC index (0.93) was significantly higher 
than of OCB (0.86; p < 0.001) but the specificity 
(0.83) was significantly lower (0.92; p < 0.001).
The accuracies were similarly high for both biomark-
ers for all three comparisons. The PPVs were higher 
for OCB (in all three comparisons p < 0.001). The 
NPV was the same for both markers (p = 0.56) in CIS 
Table 3. Diagnostic sensitivity and specificity of the FLC indices compared to OCB.
OCB KFLC p-value LFLC p-value
CIS/MS vs controls




< 0.001 0.66 (95% 
CI = 0.62–0.70)
< 0.001




< 0.001 0.86 (95% 
CI = 0.81–0.91)
0.019




1.000 0.74 (95% 
CI = 0.70–0.77)
< 0.001




< 0.001 0.92 (95% 
CI = 0.90–0.95)
0.001












0.150 0.60 (95% 
CI = 0.54–0.66)
< 0.001




< 0.001 0.86 (95% 
CI = 0.82–0.91)
0.019




0.149 0.73 (95% 
CI = 0.68–0.77)
< 0.001




< 0.001 0.83 (95% 
CI = 0.77–0.89)
0.001












< 0.001 0.75 (95% 
CI = 0.70–0.80)
< 0.001




< 0.001 0.86 (95% 
CI = 0.81–0.91)
0.019




1.000 0.80 (95% 
CI = 0.77–0.84)
< 0.001




< 0.001 0.88 (95% 
CI = 0.84–0.92)
0.002




0.001 0.73 (95% 
CI = 0.68–0.78)
< 0.001
FLC: free light chains; OCB: oligoclonal IgG bands; KFLC: kappa free light chains; LFLC: lambda free light chains; CIS: 
clinically isolated syndrome; MS: multiple sclerosis; PPV: positive predictive value; NPV: negative predictive value.
To compare the sensitivity and specificity between the two different diagnostic tools (OCB and FLC), the McNemar test was used.
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versus controls, but when pooling CIS/MS and in MS 
alone, the NPVs were slightly higher for KFLC 
(p = 0.010, p < 0.001) (see Table 3).
LFLC index. When pooling CIS and MS in one group 
(CIS/MS), the sensitivity to identify CIS/MS from con-
trols of the LFLC index (0.66) was significantly lower 
than that of OCB (0.82; p < 0.001). The specificity to 
discriminate CIS/MS from controls was also signifi-
cantly lower (0.86) than for OCD (0.92; p = 0.019).
When identifying CIS patients from controls, the 
sensitivities did differ; the LFLC index was signifi-
cantly lower than OCB (LFLC index = 0.60; 
OCB = 0.77; p < 0.001). The specificity of LFLC in 
CIS was lower than OCB (LFLC index = 0.86; 
OCB = 0.92; p = 0.019). Identifying MS patients from 
controls, the sensitivity of the LFLC index (0.75) was 
significantly lower than OCB (0.86; p < 0.001). The 
specificity (0.86) was also significantly lower than 
OCB (0.92; p = 0.019). The accuracies and NPV were 
significantly lower for LFLC than OCB for all three 
comparisons. The PPV was significantly lower for 
LFLC than OCB when comparing MS with controls, 
and in the other comparisons, the PPV of LFLC was 
similar to OCB (see Table 3).
Combination of the different tools compared to 
single measurement
Three combinations were made, KFLC index–OCB, 
LFLC index–OCB, and KFLC index–LFLC index, 
and all were compared with the analysis of OCB 
alone. Sensitivity and specificity were calculated for 
all the subgroups compared to the control group. The 
sensitivity of the combination OCB with the KFLC 
index increased to 0.88, and the specificity of this 
combination decreased to 0.83. The same results were 
obtained for the combinations of LFLC index–OCB 
and KFLC index–LFLC index compared to single 
OCB, showing a slightly higher sensitivity (LFLC 
index–OCB = 0.87, KFLC–LFLC index = 0.87) and a 
lower specificity (0.83 and 0.80, respectively).
Sensitivities and specificities in alternative 
subgroups
Including patients with the diagnosis CIS (according 
to McDonald 2005 criteria) as RRMS patients resulted 
in lower sensitivities of OCB, KFLC, and LFLC that 
were seen when comparing CIS patients with con-
trols. However, the p value did not change relevantly 
when comparing the new sensitivities for OCB, 
KFLC, and LFLC. No relevant differences were seen 
when comparing MS to control group.
No relevant differences were seen when we exclude 
patients with the CIS diagnosis according to 
McDonald 2005 criteria.
When excluding INDC from the control group, higher 
specificities were seen for OCB, KFLC, and LFLC 
when comparing CIS/MS with the controls. However, 
the p value did not change relevantly when comparing 
the new specificities of OCB, KFLC, and LFLC (data 
not shown).
Discussion
Our study indicates that the KFLC index is a valid test 
for diagnosing CIS/MS. Compared to OCB, the 
KFLC index is more sensitive at the cost of a lower 
specificity. This trade-off resulted in a higher NPV for 
the KFLC index compared to OCB, but a lower PPV. 
In addition, our results indicate that the LFLC index is 
not a valid test for diagnosing CIS/MS.
Our sensitivity and specificity for the KFLC index in 
CIS/MS were lower than a few much smaller previous 
studies,18,23,26 which reported sensitivity in the range 
of 0.93–0.95 and specificity in the range of 0.91–1.00. 
The study of Desplat-Jégo et al.9 showed a lower sen-
sitivity of 0.70 and a lower specificity of 0.82 for the 
KFLC index in MS patients. The more recent study of 
Vasilj et al.27 showed a lower sensitivity of 0.71, how-
ever a higher specificity of 0.98. The results of the 
comparison of KFLC and OCB are in line with results 
of a recent multicenter study,14 where a cut-off of 5.9 
was employed to validate KFLC in CSF as a diagnos-
tic biomarker in 60 CIS patients, 60 MS patients com-
pared to 60 OND, reporting a higher sensitivity of the 
KFLC index (0.78) compared to OCB (0.72) for diag-
nosis of CIS. In MS, the sensitivity of the KFLC and 
OCB was comparable (0.93 vs 0.93). However, the 
specificity (0.95) in CIS and MS was higher compared 
to our study. Another paper used the same 5.9 cut-off; 
this resulted in a sensitivity and specificity of 0.96 and 
0.98, respectively, in MS patients.21
This discrepancy in the crude sensitivity and specific-
ity of the KFLCs may be due to the more heterogene-
ous control group in our study compared to the 
previous studies, due to pooling of the CIS/MS group 
or the inclusion of not only clinical definite MS 
patients. For example, similar as for the OCB, KFLCs 
can be elevated in inflammatory controls,28 and thus 
specificity will be lower when included. Nevertheless, 
this is a very relevant control group in differential 
diagnosis of MS. The unprecedented large number of 
patients and the large heterogeneous control group in 
this study gave us a reflection of the real-life clinical 
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situation, thus avoiding spectrum bias, and allowed us 
to give a more representative sensitivity and specific-
ity for OCB, KFLC, and LFLC indices.
Noticeable is that the sensitivity and specificity of 
OCB to discriminate MS patients from controls were 
lower in our study than previously reported.10,29,30 
However, a meta-analysis published in 201331 (13,467 
patients) showed that the diagnostic specificity of 
OCB diminished if other inflammatory etiologies 
were considered. Therefore, the lower specificities in 
our study may also be due to inclusion of various con-
trol groups.
The cut-off in this study was calculated using a data-
driven Gaussian mixture modeling approach. We 
chose a different approach compared to other studies 
that applied, for example, receiver operating charac-
teristic (ROC) curve analysis and area under the curve 
(AUC) values,9,10,18,23,27,32 because we reasoned that 
the cut-off should be defined by biological levels 
(data driven) and not based on clinical diagnosis, 
which is an imperfect golden standard. We deter-
mined a cut-off of 6.6 for abnormal KFLC indices and 
6.9 for abnormal LFLC indices. Our cut-off for KFLC 
is in line with a previous multicenter study showing a 
KFLC index cut-off of 5.9.10 This almost comparable 
cut-off for the KFLC index in two multicenter studies 
supports its robustness and implies that it can be used 
as an universal cut-off.
There are some limitations in this study. One limita-
tion was that not all patients were diagnosed based on 
the same MS criteria; most patients by McDonald 
2010 (84%) but a few with McDonald 2005, which 
may have influenced the diagnosis of CIS patients par-
ticularly. CIS patients diagnosed before 2010 may 
very well be MS patients according to McDonald 
2010, because in the 2005 criteria, MS diagnosis was 
more stringent. None of the patients were diagnosed 
by the new 2017 criteria, because of the retrospective 
setup, and thus imaging information was not collected. 
We address this problem by pooling all CIS and MS 
patients. Another reason for pooling CIS and MS is 
that we did not have the data to test CIS converting to 
MS versus non-converting CIS, because we did not 
have follow-up data. We performed several sensitivity 
analyses in CIS or MS patients separately, and by 
reclassifying and excluding specific clinical groups 
(Table 3). In these analyses, similar results were 
observed, suggesting that our results are robust for the 
total population. Another limitation is that we did not 
repeat the OCB analysis per patient centrally, but 
relied on the original local outcomes. However, we 
received the samples and OCB status from expertise 
MS centers (participating in the BioMSeu consortium) 
using standardized protocols.33 Moreover, inter-labo-
ratory agreement is reported to be good for OCB, for 
example an inter-laboratory agreement of kappa > 0.8 
between 19 participating laboratories in Spain was 
observed.34
One more important note is that the best set up for the 
study would have been if the test population should be 
suspected MS cases and not already diagnosed with 
MS. Still, as provided in Supplemental Table 2B, we 
included various INDC and quite some patients ini-
tially suspected for demyelinating disease.
Alongside the sensitivity and specificity results of the 
indices, we found significantly increased FLC con-
centrations and quotients in CSF of CIS/MS patients 
compared to the control groups. However, our main 
focus in this study was in the FLC indices and not in 
the concentrations of the FLC. To control for blood-
CSF barrier function, we used indices instead of 
concentrations.
Combination of different markers (KFLC index–
OCB, LFLC index–OCB, and KFLC index–LFLC 
index) compared to the single measurement OCB, 
showed that the combination KFLC index–OCB com-
pared to single OCB gave a slightly higher sensitivity 
(0.88). However, the specificity became lower (0.83). 
The same results were seen in the combination LFLC 
index–OCB and KFLC index–LFLC index compared 
to single OCB. By definition, the sensitivity become 
higher and the specificity lower when you decide 
beforehand that the combination test will be positive 
when the test is positive in one of the two.
For clinical practice, the KFLC index is more accu-
rate in excluding CIS/MS compared to OCB but for 
ruling in a diagnosis of CIS/MS, analysis of OCB 
appears to be more accurate. If we replace OCB by 
KFLC in diagnostic practice, there is a slightly higher 
chance that a patient with a diagnosis different from 
MS will get the diagnosis of MS and maybe unneces-
sarily exposed to potential negative side effects of 
early treatment. Since the KFLC index is more sensi-
tive at the cost of a lower specificity, we should stress 
that replacement of OCB by the KFLC index is not 
optimal to arrive at high diagnostic certainty. 
However, with the higher sensitivity of KFLC, an ear-
lier treatment start may be considered. Whether it is 
an option to start treatment based on the KFLC result 
and clinical/MRI findings according to the novel 
McDonald criteria or whether the treatment may be 
adapted after a first-year evaluation is subject of fur-
ther studies and discussions.
Multiple Sclerosis Journal 26(8)
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In conclusion, this study indicates that the KFLC 
index is a valid tool in the diagnostic process of MS. 
Since this marker is measured by a faster and rater-
independent analytical procedure, it should be consid-
ered as a potential cost-effective replacement of the 
OCB, especially when CSF analysis will regain a 
more prominent role in the 2017 revisions of the 
McDonald criteria.
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